Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie 
Welcome,         Profile    Billing    Logout  
 19 Diseases   1 Trial   1 Trial   3388 News 


«12...3031323334353637383940...4849»
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    [VIRTUAL] SuperCAZ/AVI® medium for screening ceftazidime/avibactam-resistant Gram-negative isolates () -  May 20, 2021 - Abstract #ECCMID2021ECCMID_3481;    
    The SuperCAZ/AVI® medium is a sensitive and specific screening medium for detection of CZA-resistant bacteria regardless of their resistance mechanisms . Due to its low limit of detection, it may be used for prospective screening and epidemiological surveys of CZA-resistant isolates, the main goal being to rapidly implement infection control measures in order to limit their spread.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    [VIRTUAL] Ceftazidime-avibactam resistance in Klebsiella pneumoniae high-risk clone ST307 () -  May 20, 2021 - Abstract #ECCMID2021ECCMID_1283;    
    pneumoniae was strain 1802 (Mar 2019), which also showed reduced susceptibility to carbapenems and colistin resistance . The analysis of the evolution of CZA resistance in the high-risk clone ST307, which endemically circulates within the hospital since 2018, demonstrated that CTX-M-15 over-producing strains, showing porin depletion, have been substituted by KPC-31 producers, showing carbapenem susceptibility.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    [VIRTUAL] Overthrowing Antibiotic Resistance in Metallo-β-lactamase (MBL) Gram-negatives () -  May 9, 2021 - Abstract #WMF2021WMF_3628;    
    In the face of ATM monotherapy, VIM-2 P. aeruginosa demonstrated a capacity to form long filamentous cells tolerant to therapy. New combinatorial therapeutics involving β-lactams/β-lactam inhibitors and polymyxins showed promise to combat MBL Gram-negatives.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    [VIRTUAL] Mechanisms of Resistance to Beta-lactams in Enterobacter cloacae Complex (Poster Hall) -  May 9, 2021 - Abstract #WMF2021WMF_2642;    
    18 isolates were identified as ESBL genes-harbouring strains and 16 were screened positive for porins mutations, 10 of them carrying a mutation in either one of the two genes previously mentioned (6 having a deletion in the ompK35 gene, 3 with a ompK36 deletion and 5 mutations on different sites of the ompK36 sequence). 62 strains out of 73 resulted positives for AmpC production, 21 carried the ampD gene (3 of which also carried the ampR gene).
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    [VIRTUAL] Prospective, Multicenter Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in Carbapenem-resistant Pseudomonas Aeruginosa (CR-PA) (Poster Hall) -  May 9, 2021 - Abstract #WMF2021WMF_1737;    
    This study evaluated the performance of a previously defined phenotypic algorithm (carbapenem-resistant AND ceftazidime (CAZ) and cefepime (FEP)-non-susceptible (NS)) to guide definitive carbapenemase testing in a contemporary, global CR-PA collection...Additional minimum inhibitory concentrations (MICs) for CAZ, FEP, ceftolozane/tazobactam (C/T), and ceftazidime/avibactam (CZA) were conducted by broth microdilution and the modified carbapenem inactivation method (mCIM) was conducted at a central laboratory per CLSI...Further genotypic data of the algorithm false negative isolates may define test performance in specific enzymology. Applying CP testing to CAZ AND FEP-NS-CR-PA can streamline CP targeted testing by decreasing the number of mCIM negative isolates tested.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    [VIRTUAL] Crystal Structures of Kpc-2 β-lactamase in Complex with Triazolyl Boronic Acid Transition State Inhibitors (Poster Hall) -  May 9, 2021 - Abstract #WMF2021WMF_1651;    
    Unexpectedly, KPC-2 variants have also arisen in the clinic that seem to confer resistance to ceftazidime/avibactam, a novel β-lactam β-lactamase inhibitor therapy that has been used successfully to overcome serious infections caused by KPC-2 harboring bacteria...In cell-based assays, the MIC for cefepime (FEP) decreased from 32 to 0.5 mg/L with the addition of 4 mg/L of MB_076, and to 2 mg/L using PCF-003...Each inhibitor also made van der Waals interactions with N170. These crystal structure of KPC-2 BATSI complexes provide insights into the molecular basis of the BATIS’s high affinity for KPC-2 and could aid in the design of future BATSI inhibitors of KPC-2 and variants